author-photo

Yingbo Wang

Novartis

17

Papers

508

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Ribociclib plus fulvestrant for advanced breast cancer: health-related quality of life analyses from the MONALEESA-3 study

2020 The Breast
Show All
- Source
- Cite
- Save
Citations (6)
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
LBA7_PROverall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (34)
Using ecological propensity score to adjust for missing confounders in small area studies

2019 Biostatistics
Show All
- Source
- Cite
- Save
Citations (7)
290OPatient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Abstract P5-21-06: Alpelisib plus letrozole in estrogen receptor-Positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
346PRibociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3

2018
Show All
- Source
- Cite
- Save
Citations (9)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (381)